Nasdaq:US$15.72 (+0.06) | HKEX:HK$24.75 (+0.75) | AIM:£2.47 (+0.03)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2013-04-06

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer